Expanding the Pool in Orthotopic Heart Transplantation
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, pilot trial to test the safety and efficacy of transplantation of
hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV
Ab+/NAT+) donors to HCV seronegative recipients on the heart transplant waitlist. Treatment
and prophylaxis will be administered, using a transmission-triggered approach for the first
scenario (HCV Ab+/NAT- donors, arm 1) and a prophylaxis approach for the later scenario (HCV
Ab+/NAT+ donors, arm 2).